Literature DB >> 14664756

Peripheral neuropathy and cancer.

Arthur D Forman1.   

Abstract

Peripheral neuropathy has a major impact on quality of life and may limit the amount of treatment patients can receive. Neurotoxic agents are used increasingly in oncologic practice, yet clinicians are often unaware of the protean manifestations of neuropathy and find its management troubling. Recent knowledge about the mechanisms of neuropathic disease and new treatments may help to minimize the impact of neuropathy on this vulnerable patient population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14664756     DOI: 10.1007/s11912-996-0005-9

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  49 in total

1.  Carcinomatous neuromuscular syndromes. A clinical and quantitative electrophysiological study.

Authors:  T Paul; B C Katiyar; S Misra; G C Pant
Journal:  Brain       Date:  1978-03       Impact factor: 13.501

2.  Thalidomide neuropathy: an electrophysiologic study.

Authors:  A Lagueny; A Rommel; B Vignolly; A Taieb; M Vendeaud-Busquet; M S Doutre; J Julien
Journal:  Muscle Nerve       Date:  1986 Nov-Dec       Impact factor: 3.217

Review 3.  Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review.

Authors:  S L Collins; R A Moore; P Wiffen
Journal:  J Pain Symptom Manage       Date:  2000-12       Impact factor: 3.612

4.  Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin.

Authors:  P Lissoni; G Tancini; S Barni; F Paolorossi; A Ardizzoia; A Conti; G Maestroni
Journal:  Support Care Cancer       Date:  1997-03       Impact factor: 3.603

Review 5.  Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.

Authors:  Erick Gamelin; Laurence Gamelin; Laura Bossi; Stefan Quasthoff
Journal:  Semin Oncol       Date:  2002-10       Impact factor: 4.929

6.  Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane).

Authors:  David Cella; Amy Peterman; Stacie Hudgens; Kimberly Webster; Mark A Socinski
Journal:  Cancer       Date:  2003-08-15       Impact factor: 6.860

7.  Critical illness polyneuromyopathy: the electrophysiological components of a complex entity.

Authors:  Josef Bednarik; Zdenek Lukas; Petr Vondracek
Journal:  Intensive Care Med       Date:  2003-07-17       Impact factor: 17.440

8.  Experience with rehabilitation in the acquired immunodeficiency syndrome.

Authors:  P G O'Connell; S F Levinson
Journal:  Am J Phys Med Rehabil       Date:  1991-08       Impact factor: 2.159

9.  Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.

Authors:  V Chaudhry; E K Rowinsky; S E Sartorius; R C Donehower; D R Cornblath
Journal:  Ann Neurol       Date:  1994-03       Impact factor: 10.422

10.  Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.

Authors:  P H Hilkens; L C Pronk; J Verweij; C J Vecht; W L van Putten; M J van den Bent
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  3 in total

Review 1.  Chemotherapy-induced peripheral neuropathy: underreported and underappreciated.

Authors:  Maurie Markman
Journal:  Curr Pain Headache Rep       Date:  2006-08

2.  Establishment of a murine pancreatic cancer pain model and microarray analysis of pain‑associated genes in the spinal cord dorsal horn.

Authors:  Liqin Wang; Huihong Xu; Yanhu Ge; Hai Zhu; Dawei Yu; Weifeng Yu; Zhijie Lu
Journal:  Mol Med Rep       Date:  2017-08-04       Impact factor: 2.952

3.  Vascularization of the dorsal root ganglia and peripheral nerve of the mouse: implications for chemical-induced peripheral sensory neuropathies.

Authors:  Juan M Jimenez-Andrade; Monica B Herrera; Joseph R Ghilardi; Marina Vardanyan; Ohannes K Melemedjian; Patrick W Mantyh
Journal:  Mol Pain       Date:  2008-03-19       Impact factor: 3.395

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.